Misoprostol + Oxytocin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Postpartum Hemorrhage

Conditions

Postpartum Hemorrhage

Trial Timeline

Mar 1, 2007 → Jan 1, 2008

NCT ID

NCT01373359

About Misoprostol + Oxytocin

Misoprostol + Oxytocin is a phase 3 stage product being developed by Cipla for Postpartum Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT01373359. Target conditions include Postpartum Hemorrhage.

What happened to similar drugs?

3 of 9 similar drugs in Postpartum Hemorrhage were approved

Approved (3) Terminated (0) Active (6)

✅Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved

✅Eptacog alfa (NovoSeven)Novo NordiskApproved

✅ZULRESSO®Supernus PharmaceuticalsApproved

🔄aripiprazoleBristol Myers SquibbPhase 3

🔄SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg CapsulesBiogenPhase 3

🔄SAGE-217 + PlaceboBiogenPhase 3

🔄LPCN 1154A + PlaceboLipocinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01373359	Phase 3	Completed	Mar 1, 2007	Jan 1, 2008	Postpartum Hemorrhage

Competing Products

20 competing products in Postpartum Hemorrhage

See all competitors

Product	Company	Stage	Hype Score
Quetiapine	AstraZeneca	Phase 2	27
Azithromycin + Azithromycin and amoxicillin + Placebo	Merck	Approved	43
Eptacog alfa (NovoSeven)	Novo Nordisk	Approved	50
Eptacog alfa (activated)	Novo Nordisk	Pre-clinical	26
aripiprazole	Bristol Myers Squibb	Phase 3	40
fibrinogen concentrate + Placebo	CSL	Phase 1/2	24
SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules	Biogen	Phase 3	37
SAGE-217 + Placebo	Biogen	Phase 3	37
Zuranolone	Biogen	Pre-clinical	30
Zuranolone	Biogen	Pre-clinical	30
LPCN 1154A + Placebo	Lipocine	Phase 3	30
Goserelin 3.6 mg implant + Placebo	Brain Biotech	Pre-clinical	16
ZULRESSO (brexanolone) injection	Supernus Pharmaceuticals	Pre-clinical	20
Placebo + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
ZULRESSO®	Supernus Pharmaceuticals	Approved	37
SAGE-547	Supernus Pharmaceuticals	Phase 2	29
Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
SAGE-547 + Placebo	Supernus Pharmaceuticals	Phase 2	29
GH001	GH Research	Phase 2	21
Brexanolone	Brain Biotech	Pre-clinical	16